Skip to main content

3-FA Facts

Stimulant; Substituted amphetamine; Dopamine releasing agent

Description

3-FA (3-fluoroamphetamine) is a synthetic stimulant of the substituted amphetamine class. It releases dopamine and norepinephrine into the brain's synapses, producing the focused drive and wakefulness characteristic of amphetamine-type stimulants.[1][2]

Subjective effects include wakefulness, concentrated focus, motivation, appetite suppression, and physical stimulation. The experience is purely functional — clean drive without emotional warmth or euphoria, placing it closer to prescription amphetamine than to MDMA.

3-FA carries significant abuse liability — its abuse potential is comparable to methamphetamine[3] — and potent norepinephrine release places serious strain on the heart. Tolerance to the desired effects develops faster than tolerance to cardiac stress, so chasing the effect increases heart risk disproportionately.

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 10 mgLight20 – 30 mgCommon30 – 50 mgStrong50 – 70 mgHeavy70+ mg

Starts in 20 – 60 minLasts 4 – 6 hoursAfter-effects 2 – 6 hours

Body and dependence

Acute toxicity
Moderate
Chronic toxicity
Moderate
Physical dependence
Moderate
Psychological dependence
High
Withdrawal
Moderate
Compulsive redosing
High

Tolerance

Builds
Moderate
Fully resets after
5.5 days
Carries over to
amphetamine; methamphetamine; cocaine; other dopaminergic stimulants

Effectslikely at a common dose

Body
Appetite suppression; Dry mouth; Insomnia; Pupil dilation; Restlessness; Vasoconstriction; Stimulation; Wakefulness; +19 possible, including Muscle tension, Temperature dysregulation, Excessive sweating
Thinking
none likely · 16 possible, including Compulsive redosing urge
Feeling
Euphoria; +7 possible, including Anxiety, Dysphoria, Depression
Self
none likely · 7 possible, including Craving, Ego inflation

Who shouldn't take it

Absolute
Cardiovascular disease; Uncontrolled hypertension; Pregnancy; Concurrent MAOI use
Relative
Seizure disorders; Psychiatric conditions involving psychosis; Hyperthyroidism

Combinations61 recorded

Lethal (2)
MAOIs; Tramadol
Dangerous (33)
Anticholinergics; Atypical antipsychotics; Caffeine; Dopamine agonists; Ephedrine, Pseudoephedrine; Local anesthetics; MDMA, Amphetamines; MDMA, MDA; NDRIs (Wellbutrin); NRIs; Opioids; Psychedelics; SNRIs; SSRIs; Stimulants; 5-HTP, Tryptophan; Alpha-2 adrenergic receptor antagonist; Antihistamines; Antipsychotics; Buspirone; Clonidine, Guanfacine; DXM; GHB, Baclofen; GHB, GBL; and 9 more, see full page
Caution (23)
See full page: psychedex.org/substances/3-fa
Not graded (3)
Not listed never means safe.

Seek help immediately if

  • Chest pain; racing, pounding, or irregular heartbeat
  • Very high body temperature; heavy sweating; hot, flushed skin
  • Severe agitation, paranoia, panic, or confusion
  • Severe headache; muscle rigidity or twitching
  • Seizures
  • Signs of stroke — face drooping, one-sided weakness, slurred speech
  • Difficulty breathing; collapse or unconsciousness

What to do

  1. Call emergency services for chest pain, overheating, seizure, or unresponsiveness
  2. Move them to a cool, quiet place and reduce stimulation
  3. Cool the body — remove excess clothing, apply cool damp cloths, fan them
  4. Keep them calm; reassure — panic worsens the cardiovascular strain
  5. If seizing, protect from injury (don't restrain); recovery position afterward
  6. Monitor breathing and be ready to give rescue breaths / CPR

Most stimulant overdoses settle with cooling, a calm environment, and time. The medical danger is hyperthermia, cardiac events (arrhythmia, heart attack, stroke), and seizures — get help immediately if any appear.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL (2005) Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs — Journal of Pharmacology and Experimental Therapeutics PMID:15677348
  2. [2]
    ^Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB (2011) In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat — Journal of Pharmacology and Experimental Therapeutics doi:10.1124/jpet.110.176271
  3. [3]
    ^Anchondo O, Shetty RA, Gatch MB (2025) Locomotor and discriminative stimulus effects of fluorinated analogs of amphetamine and methamphetamine in mice and rats — Journal of Pharmacology and Experimental Therapeutics doi:10.1016/j.jpet.2025.103617
Print version
Report an issue